Psilocybin-induced changes in electroencephalography link acute and long-term effects
Marek Nikolič, Tom Froese, Pedro A. M. Mediano, Vlastimil Koudelka, Jiřı́ Horáček, Filip Tylš, Tomáš Páleníček
Journal of Psychopharmacology September 4, 2026 DOI: 10.1177/02698811261473445 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Randomized controlled trial (crossover) Placebo-controlled Double-blind Peer reviewed |
|---|---|
| Sample size | 20 |
| Population | Healthy participants (10 females) |
| Intervention | Psilocybin |
| Dose | ~0.26 mg/kg |
| Duration | 24-hour sub-acute phase with 28-day follow-up |
| Measures | Brief Psychiatric Rating Scale, Persisting Effects Questionnaire |
| Topics | Psilocybin |
| Key findings | Psilocybin acutely reduced alpha/beta power and increased gamma-band signal diversity, returning to baseline by 6 hours. Increased gamma diversity correlated with acute psychological effects (r = 0.71). At 24 hours, reduced delta/theta power correlated with positive life changes at 4 weeks (r = −0.47 to −0.57), independent of acute psychological intensity. |
Abstract
Background: Psilocybin’s therapeutic potential is neurophysiologically characterized by acute alpha power reductions and increased entropy. However, the systematic time-course of these changes from administration through the 24-hour sub-acute phase remains poorly characterized.
Methods: In a double-blind, placebo-controlled, crossover trial ( N = 20, 10 females), healthy participants received a medium dose ∼0.26 mg/kg of psilocybin. High-density resting-state electroencephalography and psychological states were assessed at baseline, 1, 3, 6, and 24 hours, with a 28-day follow-up.
Results: Psilocybin acutely decreased alpha/beta power and increased gamma-band signal diversity (1–3 hours; returning to baseline at 6 hours). Increased gamma diversity correlated with acute psychological effects (Brief Psychiatric Rating Scale, r = 0.71), with the largest increases observed in participants with lower baseline complexity. At 24 hours, reduced delta/theta power correlated with Positive Life Changes (Persisting Effects Questionnaire) at 4 weeks ( r = −0.47 to −0.57) but was independent of acute psychological intensity.
Conclusion: Our findings corroborate known acute effects while identifying a distinct sub-acute “afterglow” associated with long-term outcomes. The dissociation between acute psychology and 24-hour spectral shifts suggests that therapeutic benefits may be driven by sub-acute reductions in top-down cortical hierarchy. These results highlight the significance of the sub-acute window for psychological transformation and suggest normalized diversity as a viable baseline biomarker of individual responsiveness to psychedelic intervention.
Comparable studies
Other randomized controlled trials on psilocybin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety | 2016 | Randomized controlled trial | n = 51 |
| Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Patients with cancer-related anxiety and depression | 2016 | Double-blind, placebo-controlled, crossover trial | n = 29 |
| Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Hallucinogen-naïve adults reporting regular participation in religious or spiritual... | 2006 | Double-blind study | n = 36 |
| Trial of Psilocybin versus Escitalopram for Depression Selected group of patients with depression | 2021 | Randomized controlled trial | |
| Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder Adults aged 21 to 75 years with major depressive disorder, not currently using... | 2020 | Randomized controlled trial | n = 24 |
Citations in the library
Cites 35
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology July 1, 2008
- REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics Pharmacological Reviews June 20, 2019
- Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proceedings of the National Academy of Sciences April 11, 2016
- Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Frontiers in Pharmacology January 17, 2018
and 30 more in the library